{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T19:10:04Z","timestamp":1758568204932,"version":"3.44.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.therap.2020.10.003","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T11:56:12Z","timestamp":1603454172000},"page":"409-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study"],"prefix":"10.1016","volume":"76","author":[{"given":"Silvia","family":"Corcione","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amedeo","family":"De Nicol\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Lupia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Vladimiro","family":"Segala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pensa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Corgiat Loia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Rosa","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D\u2019Avolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Giuseppe","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.therap.2020.10.003_bib0090","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/14787210.2017.1382355","article-title":"The challenge of curbing aminoglycoside resistance: can antimicrobial stewardship programs play a critical role?","volume":"15","author":"Pitiriga","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"12","key":"10.1016\/j.therap.2020.10.003_bib0095","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1093\/cid\/cix682","article-title":"Bacterial infections after burn injuries: impact of multidrug resistance","volume":"65","author":"Lachiewicz","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.therap.2020.10.003_bib0100","first-page":"1","article-title":"Epidemiology, prevalence and risk factors for infections in burn patients: results from a regional burn centre's analysis","volume":"26","author":"Corcione","year":"2020","journal-title":"J Chemother"},{"issue":"1","key":"10.1016\/j.therap.2020.10.003_bib0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.therap.2020.10.003_bib0110","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.burns.2017.05.009","article-title":"A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients","volume":"43","author":"Lee","year":"2017","journal-title":"Burns"},{"issue":"7","key":"10.1016\/j.therap.2020.10.003_bib0115","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00134-017-4780-6","article-title":"The role of infection models and PK\/PD modelling for optimising care of critically ill patients with severe infections","volume":"43","author":"T\u00e4ngd\u00e9n","year":"2017","journal-title":"Intensive Care Med"},{"issue":"10","key":"10.1016\/j.therap.2020.10.003_bib0120","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2165\/00003088-200847100-00002","article-title":"Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients","volume":"47","author":"Blanchet","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.therap.2020.10.003_bib0125","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00005373-199309000-00010","article-title":"Aminoglycoside dosing in burn patients using first-dose pharmacokinetics","volume":"35","author":"Hollingsed","year":"1993","journal-title":"J Trauma"},{"issue":"2","key":"10.1016\/j.therap.2020.10.003_bib0130","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00004630-199703000-00005","article-title":"Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries","volume":"18","author":"Hoey","year":"1997","journal-title":"J Burn Care Rehabil"},{"issue":"1","key":"10.1016\/j.therap.2020.10.003_bib0135","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jac\/dkv291","article-title":"Impact of 30mg\/kg amikacin and 8mg\/kg gentamicin on serum concentrations in critically ill patients with severe sepsis","volume":"71","author":"Roger","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl C","key":"10.1016\/j.therap.2020.10.003_bib0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/27.suppl_C.29","article-title":"Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections","volume":"27","author":"Craig","year":"1991","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.therap.2020.10.003_bib0145","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock","volume":"45","author":"Rhodes","year":"2017","journal-title":"Crit Care Med"},{"issue":"Suppl C","key":"10.1016\/j.therap.2020.10.003_bib0150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jac\/27.suppl_C.91","article-title":"Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections","volume":"27","author":"Beaucaire","year":"1991","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.therap.2020.10.003_bib0155","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijantimicag.2006.04.015","article-title":"Increased amikacin dosage requirements in burn patients receiving a once-daily regimen","volume":"28","author":"Conil","year":"2006","journal-title":"Int J Antimicrob Agent"},{"issue":"10","key":"10.1016\/j.therap.2020.10.003_bib0160","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1093\/jac\/dkw250","article-title":"Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events?. A systematic review","volume":"71","author":"Jenkins","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.therap.2020.10.003_bib0165","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/FTD.0000000000000107","article-title":"Gentamicin and renal function: lessons from 15 years\u2019 experience of a pharmacokinetic service for extended interval dosing of gentamicin","volume":"37","author":"Plajer","year":"2015","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.therap.2020.10.003_bib0170","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572030189X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572030189X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:42Z","timestamp":1758567282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059572030189X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S004059572030189X"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.10.003","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}